Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors.
about
Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistanceImmunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapyPromoting Precision Cancer Medicine through a Community-Driven Knowledgebase.Cyclooxygenase-deficient pancreatic cancer cells use exogenous sources of prostaglandins.Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist.Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles.Processed Aloe vera gel ameliorates cyclophosphamide-induced immunotoxicity.Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapyContinuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancerClinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancersShould tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer.A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.A Nonselective Cyclooxygenase Inhibitor Enhances the Activity of Vinblastine in a Naturally-Occurring Canine Model of Invasive Urothelial Carcinoma.Metronomic chemotherapy: changing the paradigm that more is better.Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs.Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives.Low dosages: new chemotherapeutic weapons on the battlefield of immune-related disease.Metronomic chemotherapy for cancer treatment: a decade of clinical studies.Immunotherapy of HPV infection-caused genital warts using low dose cyclophosphamide.Antitumor and immunomodulatory effects of low-dose 5-FU on hepatoma 22 tumor-bearing miceRecent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure.Structure, function and carcinogenicity of metabolites of methylated and non-methylated polycyclic aromatic hydrocarbons: a comprehensive review.Current achievements and future perspectives of metronomic chemotherapy.Response assessment in metronomic chemotherapy: RECIST or PERCIST?Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinomaCollaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment.Beneficial effects of american ginseng on epididymal sperm analyses in cyclophosphamide treated ratsMetronomic dosing enhances the anti-angiogenic effect of epothilone B.The emerging low-dose therapy for advanced cancers.Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas.Protective effect of Phyllanthus fraternus against mitochondrial dysfunction induced by co-administration of cisplatin and cyclophosphamide.Therapeutic exploitation of IPSE, a urogenital parasite-derived host modulatory protein, for chemotherapy-induced hemorrhagic cystitis.
P2860
Q27023579-0FA5EC6F-7ED4-497D-AA82-3B38F6832F38Q27027093-ED1FDA12-940A-4B89-B47E-4B37436BBE95Q30487546-A5D3D11E-EA58-4543-9A3A-08F471C8CA40Q30494961-AE8F0B7F-C575-4E9A-8158-66A74BE370CAQ33942806-07670492-CEB9-4672-BBE7-E455D7706A49Q34403657-A92059E4-485A-43B5-8B40-8585EC56B5E6Q34684901-ECB3C4F4-3400-4DF1-A7E5-74BA3756EFE3Q35008766-D3AE7399-E309-4B81-A941-37B2DB23B68AQ35034703-558DE493-8736-4C79-9A88-9124E716B76DQ35918752-28A0460E-548E-49D2-8CAB-BAFB2A3A650FQ36449367-66AD2776-72DF-4E88-B215-D105F6856B2DQ36615612-4EC0D3AE-FC82-4F47-8980-A86C1A80404AQ37053781-F5EC9183-5C4D-4060-9B41-E527E1EEECDEQ37158779-85A10B7A-1F8B-4E26-BA69-641007BF3BD2Q37336482-A715AAB1-89D4-4A86-A406-66D6866809E9Q37528441-B59384A1-6498-44EC-929E-F682ECF8A394Q37728232-A5EA77E3-292E-43C7-8FD4-703FF23E1716Q38087885-05A78009-1CB0-41B9-AB22-7C2293AC7128Q38211240-F59EF27C-7E69-4718-919E-EB8FDAED492DQ38374526-BC9BD025-363C-4463-B9A5-6A22E1C3CCADQ38577917-E8CB07F8-4393-457F-B7BE-EB686936A2BEQ38740869-8BA9C90D-3005-4EEF-B20C-B881EAB6790FQ38788234-4182F84E-F340-4592-AE98-B3425A59E98EQ38916996-FDEEEFA8-E4B6-42EE-B7B5-653317C1D3A8Q39695611-FD1E39C1-3ED8-449F-AB77-5907613E34ECQ41830446-E59E23E4-80BD-437F-AD4B-6F00176B886EQ41915675-2A18FEAD-8561-4E5C-A655-F4CDF8F1E1B5Q42563683-7B47FF6C-9A92-482C-9CDD-FF7BF6806EC1Q42573450-7A4AA7EF-A93A-4EA2-8B94-EE69589D46D6Q42734547-30EFDBD9-E1A4-40B6-B767-1C9B92DE7ABAQ48006932-A5BCDA04-9780-41E6-A1B6-1CF41470376BQ52610360-998BA952-6953-4250-B697-57C8B2A3A9AD
P2860
Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Phase II clinical trial result ...... ts with advanced solid tumors.
@ast
Phase II clinical trial result ...... ts with advanced solid tumors.
@en
type
label
Phase II clinical trial result ...... ts with advanced solid tumors.
@ast
Phase II clinical trial result ...... ts with advanced solid tumors.
@en
prefLabel
Phase II clinical trial result ...... ts with advanced solid tumors.
@ast
Phase II clinical trial result ...... ts with advanced solid tumors.
@en
P2093
P1476
Phase II clinical trial result ...... ts with advanced solid tumors.
@en
P2093
Colin J Germond
Jonathan C S Noble
Mark Whissell
Pablo O Cano
Pedro G Lopez
Scott D Young
P304
P356
10.1158/1078-0432.CCR-05-2255
P407
P577
2006-05-01T00:00:00Z